Summary & Overview
HCPCS J7326: Hyaluronan (Gel-One) Intra-Articular Injection, Per Dose
HCPCS Level II code J7326 represents a single-dose vial of Hyaluronan or derivative (Gel-One) for intra-articular injection. The code identifies a marketed viscosupplement product used to provide joint lubrication and symptomatic relief for patients with degenerative joint disease in ambulatory and outpatient settings. Nationally, accurate coding for intra-articular hyaluronan products affects claims processing, benefit determination, and utilization monitoring across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for viscosupplementation, payer coverage considerations, and typical sites of service. The publication summarizes benchmarks where available, highlights recent policy and reimbursement considerations affecting injectable hyaluronans, and clarifies coding practice for per-dose billing of Gel-One.
The piece is intended for revenue cycle managers, orthopedic and rheumatology billing staff, and policy analysts seeking a national perspective on use, billing classification, and payer alignment for J7326. Data not available in the input is noted where relevant in the full publication.
Billing Code Overview
HCPCS Level II code J7326 describes Hyaluronan or derivative, gel-one, for intra-articular injection, per dose. This service is an intra-articular viscosupplementation injection intended to provide joint lubrication and pain relief, typically used for osteoarthritis of synovial joints such as the knee. The service type is an intra-articular therapeutic injection. The typical site of service is an outpatient ambulatory setting, such as an orthopedic clinic, rheumatology clinic, or ambulatory surgical center.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with symptomatic osteoarthritis of the knee presents to an outpatient orthopedic clinic for management of persistent joint pain after conservative measures (physical therapy, oral analgesics, and activity modification) provided partial relief. After clinical evaluation including history, focused musculoskeletal exam, and review of recent knee radiographs confirming osteoarthritic changes, the orthopedist recommends intra-articular viscosupplementation with a single-dose hyaluronan product, J7326 (Gel-One), to provide symptomatic relief. The visit workflow includes documentation of indication and informed consent, sterile preparation of the knee, possible local anesthetic skin wheal, ultrasound or landmark-guided intra-articular injection of the hyaluronan gel, post-procedure observation for immediate adverse reaction, and instructions for activity modification and follow-up. Typical sites of service are outpatient physician office, ambulatory surgical center, or hospital outpatient department depending on patient comorbidities and facility resources. The typical service type is a single-dose intra-articular hyaluronan injection for osteoarthritis-related joint pain (commonly knee joint).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Data not available in the input. | Data not available in the input. |